Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C

Lucía Notario, Marc Cucurull, Gabriela Cerdà, Carolina Sanz, Enric Carcereny, Ana Muñoz-Mármol, Ainhoa Hernández, Marta Domènech, Teresa Morán, Montse Sánchez-Céspedes, Marta Costa, Jose Luis Mate, Anna Esteve, Maria Saigí*

*Autor corresponent d’aquest treball

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

Resum

Approximately 20% of lung adenocarcinomas harbor activating mutations at KRAS, an oncogene with the ability to alter the tumor immune microenvironment. In this retrospective study, we examined 103 patients with KRAS-mutant lung adenocarcinoma who were treated with immunotherapy-based regimens and we evaluated the clinical outcomes according to PD-L1 expression and the type of KRAS mutation. Among all patients included, 47% carried KRAS G12C mutation whereas 53% harbored KRAS non-G12C mutations. PD-L1 status was available for 77% of cases, with higher expression among KRAS G12C tumors (p = 0.01). Better overall survival and progression-free survival were observed in high PD-L1 expression tumors, regardless of KRAS mutation type. The heterogeneous nature of KRAS-mutant tumors and the presence of other co-mutations may contribute to different outcomes to immunotherapy-based strategies.
Idioma originalEnglish
Número d’article1239000
RevistaFrontiers in Oncology
Volum13
DOIs
Estat de la publicacióPublicada - 2023

Keywords

  • Immunotherapy
  • KRAS
  • Lung adenocarcinoma
  • Non-small cell lung cancer
  • PD-L1

Fingerprint

Navegar pels temes de recerca de 'Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C'. Junts formen un fingerprint únic.

Com citar-ho